Eltrombopag
Active pharmaceutical substance formulated in Jan Aushadhi generic products for Oncology & Critical Care treatment.
🧴 Clinical Application
Take orally once daily on an EMPTY STOMACH: at least 1 hour before or 2 hours after food, and at least 2 hours before or 4 hours after mineral-containing foods or supplements (dairy products, antacids, iron, calcium, magnesium), as polyvalent cations chelate eltrombopag and reduce absorption by >70%. Titrate dose to maintain platelet count >= 50,000/microL (do not titrate to normal platelet counts).
⚠️ Side Effects
Common: Nausea, diarrhea, headache, upper respiratory tract infection, abnormal liver function tests, fatigue. Rare/Severe: Severe hepatotoxicity / hepatic failure, thromboembolic complications (portal vein thrombosis), and bone marrow reticulin fiber deposition.
🛡️ Safety Warnings
Black Box Warning: Risk of severe hepatotoxicity / liver decompensation; monitor serum transaminases and bilirubin every 2 weeks during titration, then monthly. High risk of thromboembolism if platelets rise >200,000-400,000/microL; adjust dose strictly to achieve minimum platelet count needed to avoid major bleeding. Must be taken apart from dairy products and polyvalent cations.
Jan Aushadhi Products containing Eltrombopag
Found 2 generic formulation(s) containing this active ingredient.
Eltrombopag Tablets 25mg
Eltrombopag Tablets (25mg, 50mg) is an oral, non-peptide thrombopoietin (TPO) receptor agonist on the WHO Model List of Essential Medicines. It interacts with the transmembrane domain of the human TPO receptor (c-Mpl) on megakaryocytes and hematopoietic stem cells, initiating JAK/STAT and MAPK signaling pathways that stimulate megakaryocyte proliferation and differentiation, elevating platelet counts. Indicated for chronic immune thrombocytopenia (ITP) in patients who have had an insufficient response to corticosteroids or immunoglobulins, severe aplastic anemia, and thrombocytopenia in patients with chronic hepatitis C to allow interferon therapy.
Eltrombopag Tablets 50mg
Eltrombopag Tablets (25mg, 50mg) is an oral, non-peptide thrombopoietin (TPO) receptor agonist on the WHO Model List of Essential Medicines. It interacts with the transmembrane domain of the human TPO receptor (c-Mpl) on megakaryocytes and hematopoietic stem cells, initiating JAK/STAT and MAPK signaling pathways that stimulate megakaryocyte proliferation and differentiation, elevating platelet counts. Indicated for chronic immune thrombocytopenia (ITP) in patients who have had an insufficient response to corticosteroids or immunoglobulins, severe aplastic anemia, and thrombocytopenia in patients with chronic hepatitis C to allow interferon therapy.
Brand Equivalents & Price Comparison
Compare Jan Aushadhi generic prices against popular commercial brands for Eltrombopag.
| Generic Formulation | Pack Size | Jan Aushadhi Price | Commercial Brand Equivalents | Avg. Commercial Price | Savings |
|---|---|---|---|---|---|
| Eltrombopag Tablets 25mg | 7's | ₹299.06 | ELROMO, REBOPAG, THROMPLAT, PLATIFY, ADSTROM | ₹1125.70 | 73% Save |
| Eltrombopag Tablets 50mg | 7's | ₹464.06 | ELROMO, PLATIFY, ADSTROM, THROMPLAT | ₹1806.83 | 74% Save |
Frequently Asked Questions (FAQ)
Get answers to common queries about Eltrombopag generics.